News | February 23, 2024
AstraZeneca completes acquisition of Gracell
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Subscribe To Our Newsletter & Stay Updated
